Intech Investment Management LLC Sells 103,053 Shares of Solventum Corporation $SOLV

Intech Investment Management LLC reduced its holdings in shares of Solventum Corporation (NYSE:SOLV) by 92.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,669 shares of the company’s stock after selling 103,053 shares during the quarter. Intech Investment Management LLC’s holdings in Solventum were worth $633,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. CYBER HORNET ETFs LLC acquired a new stake in shares of Solventum during the 2nd quarter valued at $28,000. Deseret Mutual Benefit Administrators grew its holdings in shares of Solventum by 78.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after purchasing an additional 163 shares during the last quarter. MUFG Securities EMEA plc bought a new stake in shares of Solventum during the second quarter worth about $31,000. State of Wyoming acquired a new stake in Solventum during the 2nd quarter worth approximately $33,000. Finally, MTM Investment Management LLC bought a new stake in Solventum during the 2nd quarter worth approximately $40,000.

Solventum Stock Down 1.5%

Solventum stock opened at $67.57 on Wednesday. Solventum Corporation has a fifty-two week low of $60.70 and a fifty-two week high of $88.20. The firm’s 50-day simple moving average is $77.14 and its 200 day simple moving average is $76.13. The stock has a market cap of $11.72 billion, a PE ratio of 7.62, a price-to-earnings-growth ratio of 1.12 and a beta of 0.40. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.96 billion. During the same quarter last year, the company posted $1.41 earnings per share. The firm’s quarterly revenue was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Research analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum announced that its board has initiated a stock buyback plan on Thursday, November 20th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to buy up to 7.5% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

A number of equities analysts have recently commented on SOLV shares. Stifel Nicolaus lifted their price target on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Mizuho set a $100.00 target price on Solventum and gave the company an “outperform” rating in a report on Tuesday, January 20th. Wells Fargo & Company lowered their target price on shares of Solventum from $86.00 to $83.00 and set an “equal weight” rating for the company in a research note on Friday, February 27th. Finally, KeyCorp increased their price target on Solventum from $97.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday, February 27th. Seven equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $93.70.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.